Find or Sell any Parts for Your Vehicle in USA

Drum Brake Shoe-duralast Rear Duralast By Autozone 631 on 2040-parts.com

US $12.00
Location:

Grand Rapids, Michigan, United States

Grand Rapids, Michigan, United States
Condition:New Manufacturer Part Number:631 Quantity Sold:sold individually Placement on Vehicle:Rear SKU:54462 Brand:DURALAST

as shown new duralast brake shoes 631 fits Nissan frontier and others

2012 Land Rover Discovery 4 tweaks revealed

Wed, 06 Jul 2011

2012 Land Rover Discovery 4 - all round good tweaking You’ve got to go forward, or you’re already going back. Or so the saying goes. Which is no doubt why Land Rover has managed to send us a 2,750 word press release to tell us all the changes they have wrought to the 2012 Discovery 4.

Revealed: the most expensive areas for car insurance

Mon, 18 Aug 2014

A study by AA Insurance has found that drivers in London are paying the most for their car insurance – with the average premium costing a whopping £922.44. And – despite a recent fall in car insurance premiums – the average cost could soon increase, with some areas already noticing insurance getting more expensive. Top 25 new cars that are cheap to insure Cheapest cars to insure for 17-18 year olds The AA found that car insurance is the most expensive in London, followed by the IG postal area (including Ilford, Barking and Chigwell), with an average premium of £912.07.

Autonomous cars on British roads by January 2015 – Vince Cable

Wed, 30 Jul 2014

By Tim Pollard Motor Industry 30 July 2014 09:18 The British government today announced new laws to allow autonomous cars on UK roads by 2015, prompting a review of the Highway Code and new legal measures to make sure driverless cars comply with current motoring law. Business secretary Vince Cable attended an event at the motor industry test facility at MIRA in the Midlands to unveil the measures, which include a £10 million regional fund for cities to apply to become a driverless car test area. Up to three cities will be selected to share the funding for trials that are expected to last between 18-36 months.